S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:SIBN

SI-BONE Stock Forecast, Price & News

$18.90
-0.46 (-2.38%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$18.69
$19.51
50-Day Range
$18.75
$24.80
52-Week Range
$18.48
$37.21
Volume
344,925 shs
Average Volume
327,010 shs
Market Capitalization
$632.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41
30 days | 90 days | 365 days | Advanced Chart
Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.


SI-BONE logo

About SI-BONE

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Headlines

SI-BONE (NASDAQ:SIBN) Shares Gap Down to $20.02
November 30, 2021 |  americanbankingnews.com
SI-BONE (NASDAQ:SIBN) Sets New 1-Year Low at $19.11
November 29, 2021 |  americanbankingnews.com
SI-BONE, Inc. (NASDAQ:SIBN) CEO Sells $104,108.03 in Stock
November 17, 2021 |  americanbankingnews.com
SI-BONE Target of Unusually Large Options Trading (NASDAQ:SIBN)
November 15, 2021 |  americanbankingnews.com
Comparing SI-BONE (NASDAQ:SIBN) and Beauty Health (NASDAQ:SKIN)
November 15, 2021 |  americanbankingnews.com
JMP Securities Lowers SI-BONE (NASDAQ:SIBN) Price Target to $36.00
November 9, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SIBN
Fax
N/A
Employees
295
Year Founded
N/A

Sales & Book Value

Annual Sales
$73.39 million
Book Value
$4.29 per share

Profitability

Net Income
$-43.70 million
Pretax Margin
-58.66%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,146,000
Market Cap
$632.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/14/2022

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

362nd out of 1,390 stocks

Surgical & Medical Instruments Industry

39th out of 126 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












SI-BONE (NASDAQ:SIBN) Frequently Asked Questions

Is SI-BONE a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

How has SI-BONE's stock been impacted by Coronavirus?

SI-BONE's stock was trading at $15.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SIBN shares have increased by 23.4% and is now trading at $18.90.
View which stocks have been most impacted by COVID-19
.

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for SI-BONE
.

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The firm earned $22.29 million during the quarter, compared to analyst estimates of $22.71 million. SI-BONE had a negative trailing twelve-month return on equity of 32.49% and a negative net margin of 58.66%. During the same period in the prior year, the firm posted ($0.33) earnings per share.
View SI-BONE's earnings history
.

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE issued an update on its FY 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89 million-$90 million, compared to the consensus revenue estimate of $92.71 million.

What price target have analysts set for SIBN?

7 equities research analysts have issued 1-year target prices for SI-BONE's stock. Their forecasts range from $32.00 to $40.00. On average, they anticipate SI-BONE's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

When did SI-BONE IPO?

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.20%), American Century Companies Inc. (3.03%), Morgan Stanley (2.31%), Macquarie Group Ltd. (2.05%), Geode Capital Management LLC (1.51%) and Impax Asset Management Group plc (1.41%). Company insiders that own SI-BONE stock include Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp and W Carlton Reckling.
View institutional ownership trends for SI-BONE
.

Which major investors are selling SI-BONE stock?

SIBN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Next Century Growth Investors LLC, Principal Financial Group Inc., Two Sigma Investments LP, Invesco Ltd., Two Sigma Advisers LP, Russell Investments Group Ltd., and Goldman Sachs Group Inc.. Company insiders that have sold SI-BONE company stock in the last year include Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, and Michael A Pisetsky.
View insider buying and selling activity for SI-BONE
or view top insider-selling stocks.

Which major investors are buying SI-BONE stock?

SIBN stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Morgan Stanley, Eversept Partners LP, Tamarack Advisers LP, Altium Capital Management LP, and Bank of New York Mellon Corp.
View insider buying and selling activity for SI-BONE
or or view top insider-buying stocks.

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $18.90.

How much money does SI-BONE make?

SI-BONE has a market capitalization of $632.96 million and generates $73.39 million in revenue each year. The company earns $-43.70 million in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 295 workers across the globe.

What is SI-BONE's official website?

The official website for SI-BONE is www.si-bone.com.

Where are SI-BONE's headquarters?

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at (408) 207-0700 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.